For research use only. Not for therapeutic Use.
Relebactam（Cat No.:I000621）is a β-lactamase inhibitor used in combination with imipenem and cilastatin to treat severe bacterial infections caused by multidrug-resistant Gram-negative bacteria. By inhibiting β-lactamase enzymes, relebactam protects imipenem from degradation, restoring its efficacy against resistant strains, including those that produce carbapenemases. This combination is effective against complex infections, such as complicated urinary tract infections (cUTIs) and complicated intra-abdominal infections (cIAIs). Relebactam’s ability to extend the activity of imipenem against resistant pathogens makes it a valuable tool in combating antibiotic-resistant bacterial infections.
| Catalog Number | I000621 |
| CAS Number | 1174018-99-5 |
| Molecular Formula | C12H20N4O6S |
| Purity | 98% |
| Target | beta-lactamase |
| Target Protein | P62593,P0AD63 |
| Solubility | 10 mM in DMSO |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IUPAC Name | [(2S,5R)-7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate |
| InChI | InChI=1S/C12H20N4O6S/c17-11(14-8-3-5-13-6-4-8)10-2-1-9-7-15(10)12(18)16(9)22-23(19,20)21/h8-10,13H,1-7H2,(H,14,17)(H,19,20,21)/t9-,10+/m1/s1 |
| InChIKey | SMOBCLHAZXOKDQ-ZJUUUORDSA-N |
| SMILES | C1C[C@H](N2C[C@@H]1N(C2=O)OS(=O)(=O)O)C(=O)NC3CCNCC3 |
| Reference | </br>1:<i>In Vitro</i> Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 – Results from the SMART Global Surveillance Program. Lob SH, Hackel MA, Kazmierczak KM, Young K, Motyl MR, Karlowsky JA, Sahm DF.Antimicrob Agents Chemother. 2017 Mar 20. pii: AAC.02209-16. doi: 10.1128/AAC.02209-16. [Epub ahead of print] PMID: 28320716 </br>2:Invitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 – Results from the SMART global surveillance program. Lob SH, Hackel MA, Kazmierczak KM, Hoban DJ, Young K, Motyl MR, Karlowsky JA, Sahm DF.Diagn Microbiol Infect Dis. 2017 Jun;88(2):171-176. doi: 10.1016/j.diagmicrobio.2017.02.018. Epub 2017 Mar 2. PMID: 28291628 </br>3:Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection. Lucasti C, Vasile L, Sandesc D, Venskutonis D, McLeroth P, Lala M, Rizk ML, Brown ML, Losada MC, Pedley A, Kartsonis NA, Paschke A.Antimicrob Agents Chemother. 2016 Sep 23;60(10):6234-43. doi: 10.1128/AAC.00633-16. Print 2016 Oct. PMID: 27503659 Free PMC Article</br>4:In Vitro Evaluation of the Activity of Imipenem-Relebactam against 451 Recent Clinical Isolates of Bacteroides Group and Related Species. Snydman DR, Jacobus NV, McDermott LA.Antimicrob Agents Chemother. 2016 Sep 23;60(10):6393-7. doi: 10.1128/AAC.01125-16. Print 2016 Oct. PMID: 27480858 Free PMC Article</br>5:Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City. Lapuebla A, Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, Quale J.Antimicrob Agents Chemother. 2015 Aug;59(8):5029-31. doi: 10.1128/AAC.00830-15. Epub 2015 May 26. PMID: 26014931 Free PMC Article |
